Investment Team
Partner, Healthcare Flagship
Olivier Lieven joined Astorg in 2015 and is a Partner on the Healthcare team. He also serves as Co-Head of the New York Office. Since joining Astorg, Olivier has been involved in multiple healthcare investments, including HRA Pharma, Echosens, Clario, Cytel, OPEN Health, and Nexpring. He was alsoinstrumental in leading the expansion of the Astorg Healthcare platform in the US. Prior to joining Astorg, Olivier worked at 3i in the infrastructure investment division.
Olivier is based in New York and is a graduate of École Polytechnique, École des Ponts et Chaussées, and the Paris School of Economics.
Nexpring Health
Nexpring Health is a global leader in Assisted Reproductive Technology(ART), providing consumables and equipment for in-vitro fertilization(IVF) procedures to hospitals, clinics and IVF labs across 115+ countries.
Investment year: 2024
Healthcare In Portfolio
OPEN Health
OPEN Health is a global leading medical affairs and market access platform serving the pharma industry.
Investment year: 2022
Healthcare In Portfolio
Cytel
Cytel is widely recognized as the industry pioneer of adaptive clinical trials technology and a thought-leader in biostatistical science.
Investment year: 2021
Healthcare In Portfolio
Clario
Clario delivers leading endpoint technology solutions for clinical trials.
Investment year: 2020
Healthcare In Portfolio
Echosens
Echosens is a specialized diagnostic company providing non-invasive medical devices and services to support physicians in their diagnostic and monitoring of chronic liver diseases.
Investment year: 2018
Healthcare In Portfolio
HRA Pharma
HRA is an innovative OTC pharma company with leading positions in Europe and in the US.
Investment year: 2016
Healthcare Realised